Advertisement

Topics

Latest "Sumatriptan Naproxen combination other oral triptans Migraine Disorders" News Stories

04:01 EST 20th January 2019 | BioPortfolio

Here are the most relevant search results for "Sumatriptan Naproxen combination other oral triptans Migraine Disorders" found in our extensive news archives from over 250 global news sources.

More Information about Sumatriptan Naproxen combination other oral triptans Migraine Disorders on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Sumatriptan Naproxen combination other oral triptans Migraine Disorders for you to read. Along with our medical data and news we also list Sumatriptan Naproxen combination other oral triptans Migraine Disorders Clinical Trials, which are updated daily. BioPortfolio also has a large database of Sumatriptan Naproxen combination other oral triptans Migraine Disorders Companies for you to search.

Showing "Sumatriptan Naproxen combination other oral triptans Migraine Disorders" News Articles 1–25 of 7,000+

Saturday 19th January 2019

Kv1.3 Therapeutics Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 11122018] Prices from USD $250

SummaryKv1.3 TherapeuticsKv1.3 formerly KPI Therapeutics Inc, is a biotechnology company that develops therapies for autoimmunity and chronic pain. The company provides pipeline products such as Dalazatide, a synthetic peptide for the treatment of autoimmune disorders; KPI190, an eye drop developed for several eye diseases such as uveitis, dry eye syndrome; and KPI150, a topical cream for atopic ...


Why doesn’t the allied health field play a larger role in the care of patients?

The Association of Schools of Allied Health Professionals defines the allied health sector as “professionals that are involved with the delivery of health or related services pertaining to the identification, evaluation, and prevention of diseases and disorders; dietary and nutrition services; rehabilitation and health systems management, among others. Allied health professionals, to name a few,...

Friday 18th January 2019

Proteus Launches Digital Cancer Chemotherapy Pill Program for Cancer Patients

Proteus Digital Health, Inc., Fairview Health Services, and the University of Minnesota Health announced that for the first time cancer patients are using digital oncology medicines to support treatment regimens and improve outcomes. This advancement helps patients complete oral chemotherapy cycles while oncologists gain new insights into their patients’ treatment progress and overall health...


Brainsway again attempts IPO on Nasdaq

Brainsway Ltd. (deep transcranial magnetic stimulation device (TMS) for psychiatric, neurological, and addiction disorders) i...

FDA Advisory Committee Votes on Zynquista (sotagliflozin) as Treatment for Adults With Type 1 Diabetes

The Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) today voted eight to eight on the question of whether the overall benefits of Lexicon Pharmaceutical’s (Nasdaq: LXRX) Zynquista (sotagliflozin) outweighed the risks to support approval. As quoted in the press release: Sotagliflozin is an investigational oral dual SGLT1 and SGLT2 … ...

Does Marijuana Use Cause Schizophrenia?

As the drug becomes more popular, concerns have been raised that its use can lead to psychotic disorders. Here’s what scientists know for sure, and what they don’t.

Joint Disorders | Medscape

Joint pain and disorders are primarily caused by osteoarthritis, which affects over 20 million people in the United States annually.

FDA Committee Votes in Favor of Approving Zynquista, an Investigational Dual SGLT1 and SGLT2 Inhibitor, as Treatment for Type 1 Diabetes

PARIS and THE WOODLANDS, TX – January 17, 2019 – The Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) today voted eight to eight on the question of whether the overall benefits of Zynquista(TM)* (sotagliflozin) outweighed the risks to support approval. Sotagliflozin is an investigational oral dual SGLT1 and SGLT2 inhibitor &...

OliX Announces Clinical Candidate Nomination for the Treatment of Geographic Atrophy

SUWON, South Korea, Jan. 18, 2019 /PRNewswire/ -- OLX10020, a cell-penetrating asymmetric siRNA ("cp-asiRNA") against a novel target (Undisclosed) for treatment of Geographic Atrophy ("GA"), proved effective in both Dry and Wet AMD animal models and to be submitted an IND application to the FDA to initiate a Phase 1 trial this year.

F.D.A. Panel Split on Whether to Approve New Diabetes Drug

The advisory committee voted 8-8 on approving the drug, to be called Zynquista, which would be the first oral medication for people with Type 1 diabetes.

Which Came First: Cannabis Use Or Psychotic Disorders? Scientists Weigh In On Dangers, Myths

Top scientists who specialize in marijuana research are divided over whether the drug can lead to disorders like schizophrenia. “I’ve been doing this research for 25 years, and it’s polarizing even among academics,” said Margaret Haney, a professor of neurobiology at Columbia University Medical Center. Other public health news focuses on climate change's dangers; pain's origins in the brai...

A new class of migraine therapies that target calcitonin gene-related peptide are poised to transform the market - find out more in this analysis https://go.nature.com/2RCPbaX pic.twitter.com/eYim19GxwD

A new class of migraine therapies that target calcitonin gene-related peptide are poised to transform the market - find out more in this analysis https://go.nature.com/2RCPbaX  pic.twitter.com/eYim19GxwD

Oral Hepatoselective Glucokinase Activator Promising in T2DM

FRIDAY, Jan. 18, 2019 -- Use of the oral hepatoselective glucokinase activator (GKA) TTP399 for type 2 diabetes does not cause hypoglycemia and has no detrimental effect on plasma lipids or liver enzymes, according to a study published online Jan....

FDA Panel Has Tie Vote on New Type 1 Diabetes Drug

FRIDAY, Jan. 18, 2019 -- A U.S. Food and Drug Administration advisory panel vote on whether to recommend approval of the first oral medication for type 1 diabetes ended in an 8-8 tie Thursday. Despite that result, the FDA is expected to decide by...

Autifony Therapeutics achieves first milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders

Stevenage, UK – 18 January 2019 – Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat serious disorders of the nervous system, today announced that the first milestone has successfully been achieved under Autifony’s option agreement with Boehringer Ingelheim. As announced previously, Boehringer Ingelheim acquired an exc...

Medtronic begins trial of SynchroMed II intrathecal drug delivery system

Also known intrathecal drug delivery system, SynchroMed II is being tested as an alternative to oral opioids for patients with chronic intractable non-malignant primary back pain with or The post Medtronic begins trial of SynchroMed II intrathecal drug delivery system appeared first on Compelo Medical Devices.

FDA advisers divided on Sanofi’s oral type 1 diabetes drug

The future of Sanofi and Lexicon’s oral diabetes drug Zynquista hangs in the balance after an FDA advisory committee was split on whether the drug would benefit patients. The Endocrinologic and Metabolic Drugs Advisory Committee voted eight to eig...

FDA advisers split on Lexicon-Sanofi diabetes drug

The panel could not agree on whether the benefits outweigh the risks of what could be the first oral anti-diabetic drug in the U.S. for Type 1 patients. 

ERYTECH Presents TRYbeCA-1 Trial-in-Progress Poster at the 2019 ASCO GI Annual Meeting

LYON, France and CAMBRIDGE, Mass., Jan. 18, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, announced that a poster entitled "TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemoth...

Menopausal Hormone Therapy and Risk for Venous Thromboembolism: Route of Administration Matters

Case-control study of two large U.K. databases indicates that transdermal estrogen is safer than oral.

Thursday 17th January 2019

Getting closer to a cure for migraine

Digital medicine startup Proteus Digital Health pushes into oncology

Proteus’ new oral oncology drug is a digital version of capecitabine, a common chemotherapy medication often used to treat breast

Sanofi: FDA advisory committee votes on Zynquista(TM) (sotagliflozin) as treatment for adults with type 1 diabetes

FDA advisory committee votes on Zynquista(TM) (sotagliflozin) as treatment for adults with type 1 diabetes PARIS and THE WOODLANDS, TX - January 17, 2019 - The Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) today voted eight to eight on the question of whether the overall benefits of Zynquista(TM)* (sotagliflozin) outweighed...

'Happiness' exercises can boost mood in those recovering from substance use disorder

(Massachusetts General Hospital) Brief, text-based, self-administered exercises can significantly increase in-the-moment happiness for adults recovering from substance use disorders, report researchers at the Massachusetts General Hospital Recovery Research Institute

Vaccinex Presented Previously Disclosed Data from Ongoing Phase 1/2 Trial of VX15/2503

Vaccinex (Nasdaq:VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, today announces vice president of preclinical research, Elizabeth Evans, Ph.D., provided a podium presentation at the Cambridge ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks